Biosensia’s COO Diarmuid Flavin to present ‘RapiPlex’ point of care platform at the AACC 2010 Annual Meeting and Clinical Lab Expo in Anaheim.
Biosensia will be presenting and exhibiting at the AACC 2010 (American Association of Clinical Chemistry) Conference at the Anaheim Convention Center, in Anaheim, CA, July 27-29th 2010. The AACC 2010 is the largest clinical laboratory exposition in the world.
In addition to exhibiting at the AACC 2010 Biosensia will be presenting at an Industry Workshop in association with Diagnostic Consulting Network and Symbient Product Development on July 28th, 2010 at 7am in the Anaheim Marriott Hotel. This workshop, which is open to all, will focus on the latest technologies for quantitative rapid tests used in diagnostics and will showcase Biosenisa’s highly innovative, practical and cost-effective point of care platform ‘RapiPlex’.
Workshop Title: Practical Development of Quantitative, High Sensitivity Fluorescent Rapid Assay Systems
Presenters: Biosensia, Diagnostic Consulting Network and Symbient Product Development
Location: Anaheim Marriott Hotel
Time and Date: July 28th, 2010 at 7am. Breakfast will be provided.
Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics. Its latest innovation, RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications. With RapiPlex, Biosensia is primed to expand the capabilities of in-vitro diagnostic technologies by balancing innovation which improves turnaround times, specificity and sensitivity with the need to produce cost-effective, user friendly systems.
Diarmuid Flavin, Chief Operating Officer of Biosensia will introduce Biosensia’s novel point of care platform ‘RapiPlex’ to conference attendees. Diarmuid has over 15 years’ management experience in the healthcare industry. From diagnostics to medical devices and sterile pharmaceutical manufacture, Diarmuid has experience across a number of sectors and he has worked with a range of companies including Abbott Vascular, Bioniche, and DeRoyal Europe Ltd .
Diarmuid is delighted to be attending the AACC Annual Meeting. According to Diarmuid “Since Biosensia began commercializing its ‘RapiPlex’ platform we’ve seen substantive market demand across a range of diagnostic applications. Our presence at AACC is a great opportunity for Biosensia as it will afford customers, investors, and the general public the opportunity to learn more about our company, our technology, and the solutions we offer”.
Biosensia will be exhibiting at the AACC 2010 Conference at the Anaheim Convention Center, July 27-29. Attendees wishing to meet with Biosensia and learn more about the company, its technology, and the solutions it offers should visit us at booth #1016. If you would like to set up a private meeting time, please contact Diarmuid Flavin at email@example.com or +353 1 7163650.